| Metastasis from malignant neoplasm of colon and/or rectum
Lumakras vs Cyramza
Side-by-side clinical, coverage, and cost comparison for metastasis from malignant neoplasm of colon and/or rectum.Deep comparison between: Lumakras vs Cyramza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCyramza has a higher rate of injection site reactions vs Lumakras based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cyramza but not Lumakras, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lumakras
Cyramza
At A Glance
Oral
Once daily
KRAS G12C inhibitor
IV infusion
Every 2 weeks
VEGFR2 antagonist
Indications
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
Dosing
Non-Small Cell Lung Carcinoma 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily as a single agent until disease progression or unacceptable toxicity.
Metastasis from malignant neoplasm of colon and/or rectum 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily in combination with panitumumab until disease progression or unacceptable toxicity; administer the first dose prior to the first panitumumab infusion.
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) - NSCLC Diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, cough.
Most common (>=20%) - mCRC with panitumumab Rash, dry skin, diarrhea, stomatitis, fatigue, musculoskeletal pain.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, pneumonia, diarrhea (NSCLC); sepsis, intestinal obstruction (mCRC with panitumumab).
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Pharmacology
KRAS G12C inhibitor; sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS, thereby blocking tumor cell growth and promoting apoptosis in KRAS G12C tumor cell lines.
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lumakras
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lumakras
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lumakras
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Cyramza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LumakrasView full Lumakras profile
CyramzaView full Cyramza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.